Jump Financial’s MaxCyte MXCT Stock Holding History

Jump Financial’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,631	Closed	-$16.5K	–	2221
2025 Q4	$16.5K	Buy	+10,631	New	+$17K	﹤0.01%	1886
2022 Q1	–	Sell	-20,500	Closed	-$209K	–	1777
2021 Q4	$209K	Buy	+20,500	New	+$220K	0.01%	1094

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $88.9M AUM

Jump Financial's MXCT Position: Q1 2026 in Review

Jump Financial sold out of MaxCyte (MXCT) in Q1 2026, closing a stake of 10,631 shares — an estimated $16.5K sold.

Jump Financial first reported a position in MXCT in Q4 2021 and held it in 2 quarters. The position peaked at $209K in Q4 2021. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

Jump Financial reported no remaining MaxCyte position as of Q1 2026 after selling out during the quarter.
Jump Financial sold 10,631 MaxCyte shares in Q1 2026, an estimated $16.5K.
Jump Financial first reported a position in MaxCyte in Q4 2021 and held it in 2 quarters.
Jump Financial's MaxCyte position peaked at $209K in Q4 2021.
130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.